

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035027 A1

(51) International Patent Classification⁷: A61K 9/20, 31/551, A61P 25/18

(21) International Application Number: PCT/SI2003/000036

(22) International Filing Date: 16 October 2003 (16.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: P-0200255 18 October 2002 (18.10.2002) SI

(71) Applicant (for all designated States except US): KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO [SI/SI]; Smarjeska c. 6, 8501 Novo mesto (SI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PERC, Stanka [SI/SI]; Sinji Vrh 18, 8344 Vinica pri Crnomlju (SI). BANKO, Ivanka [SI/SI]; Dvor 18a, 8361 Dvor (SI). KOLENC, Ivanka [SI/SI]; Segova 4, 8000 Novo mesto (SI).

(74) Agent: PATENTNA PISARNA D.O.O.; Copova 14, POB 1725, 1001 Ljubljana (SI).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/035027 A1

(54) Title: PHARMACEUTICAL FORMULATION OF OLANZAPINE

(57) Abstract: A pharmaceutical formulation comprising a homogeneous mixture of (a) olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a monosaccharide and/or oligosaccharide, (c) a polysaccharide and, optionally, further ingredients .

INTERNATIONAL SEARCH REPORT

International application No
PCT/31 03/00036

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/20 A61K31/551 A61P25/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 830 858 A (LILLY CO ELI) 25 March 1998 (1998-03-25) cited in the application page 5, line 1-51; example 3 -----	1-11, 14-16
E	WO 03/086361 A (DESHMUKH ABHIJIT MUKUND ; DHANORKAR VIPIN TATYASAHEB (IN); DIVI MURALI) 23 October 2003 (2003-10-23) example 7-9 example 13 -----	1,8,10, 11,15,16

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

13 February 2004

Date of mailing of the international search report

23/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Borst, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/SI 03/00036

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0830858	A 25-03-1998	AU	719788 B2	18-05-2000
		AU	4423097 A	17-04-1998
		BR	9713215 A	04-04-2000
		CA	2266448 A1	02-04-1998
		CN	1230883 A	06-10-1999
		CZ	9900988 A3	15-12-1999
		EA	1610 B1	25-06-2001
		EP	0830858 A1	25-03-1998
		HU	9904065 A2	28-04-2000
		ID	21762 A	22-07-1999
		JP	2001501207 T	30-01-2001
		KR	2000048540 A	25-07-2000
		NO	991405 A	23-03-1999
		PL	332503 A1	13-09-1999
		TR	9900651 T2	21-07-1999
		WO	9813027 A1	02-04-1998
		US	2001020032 A1	06-09-2001
		ZA	9708517 A	23-03-1999
WO 03086361	A 23-10-2003	WO	03086361 A1	23-10-2003

Claims

1. A pharmaceutical formulation comprising a homogeneous mixture of (a) olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a monosaccharide and/or oligosaccharide, and (c) a polysaccharide.
2. The pharmaceutical formulation of claim 1 comprising 40 to 80 weight % of the component (b).
3. The pharmaceutical formulation of any one of claims 1 to 2 comprising 10 to 40 weight % of the polysaccharide.
4. The pharmaceutical formulation of any one of claims 1 to 3 additionally comprising (d) up to 15 weight % of a disintegrant.
5. The pharmaceutical formulation of any one of claims 1 to 4 additionally comprising (e) 5 to 20 weight % of a binder.
6. The pharmaceutical formulation of any one of claims 1 to 5 additionally comprising (f) 0.25 to 5 weight % of a lubricant.
7. The pharmaceutical formulation of any one of claims 1 to 6 additionally comprising (g) 0.1 to 0.5 weight % of a glidant.
8. The pharmaceutical formulation of any one of claims 1 to 7, wherein the component (b) is selected from the group consisting of lactose, sucrose, dextrose, sorbitol, mannitol, lactitol, and mixtures thereof.
9. The pharmaceutical formulation of claim 8, wherein the component (b) is lactose.

10. The pharmaceutical formulation of any one of claims 1 to 9, wherein the polysaccharide is selected from the group consisting of starch, cellulose, and mixtures thereof.
11. The pharmaceutical formulation of claim 10, wherein the polysaccharide is cellulose.
12. The pharmaceutical formulation of claim 11, wherein a mixture of 20 to 30 weight % of cellulose and 70 to 80 weight % of lactose is used as the components (b) and (c).
13. The pharmaceutical formulation of claim 12 comprising 70 to 90 weight % of a mixture of 20 to 30 weight % of cellulose and 70 to 80 weight % of lactose; 8 to 12 weight % of a binder; 3 to 10 weight % of a disintegrant; 0.3 to 2 weight % of a lubricant; and 0.2 to 0.4 weight % of a glidant.
14. The pharmaceutical formulation of any one of claims 1 to 13 obtainable by direct compression.
15. The pharmaceutical formulation of any one of claims 1 to 14 comprising olanzapine as the only pharmaceutically active ingredient.
16. The pharmaceutical formulation of any one of claims 1 to 15 having the form of an uncoated tablet.
17. A process for preparing a stable pharmaceutically solid oral formulation according to any one of claims 1 to 16 comprising combining (a) olanzapine or a pharmaceutically acceptable salt thereof with (b) a monosaccharide and/or oligosaccharide, (c) a polysaccharide and optionally one or more of components (d) to (g), followed by a direct compression of the mixture into tablets in the absence of any solvent.